
Ariad founder retires
pharmafile | May 11, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Ariad, harvey Berger
Dr Harvey Berger the founder of US pharma firm Ariad Pharmaceuticals has announced his decision to retire as chairman and chief executive officer, upon the appointment of a successor.
Berger will retire at the end of December if the vacancy remains unfulfilled at that point, but Ariad says it has begun a comprehensive search to identify the right candidate.
Berger has also agreed to serve as a special advisor to the board and the new chief executive upon his retirement to facilitate a smooth transition.
Berger says: “I am proud to have worked with so many incredibly talented employees and together to have achieved so much for cancer patients in need of new treatment options where none exist. I had always anticipated retiring around age 65, which I will reach at the time of our upcoming annual meeting. My colleagues and I are all driven by our passion for helping cancer patients, and I hope Ariad will always be recognised for this dedication.”
Berger founded Ariad 23 years ago and has served as its chairman and chief executive officer since 1991. He has led the company’s growth into and nder his leadership its scientists have discovered five new drug candidates.
Related Content

Takeda to acquire Ariad in $5.2 billion deal
Takeda has acquired US drug maker, Ariad Pharmaceuticals, in a deal worth $5.2 billion. Takeda …

Incyte acquires Ariad’s European operations in $140 million deal
Incyte (NASDAQ: INCY) has entered into an agreement with Ariad Pharmaceuticals (NASDAQ: ARIA) that will …

EMA keeps Ariad cancer drug on the market
The EMA has recommended Ariad’s leukaemia drug Iclusig (ponatinib) should continue to be used under …






